Journal of Addictive Diseases最新文献

{"title":"President's message.","authors":"Darrin Mangiacarne","doi":"10.1080/10550887.2025.2465947","DOIUrl":"https://doi.org/10.1080/10550887.2025.2465947","url":null,"abstract":"","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"1-2"},"PeriodicalIF":1.6,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breaking the cycle: a systematic review of neurobiological mechanisms and psychotherapeutic innovations in ketamine addiction.","authors":"Christopher Lomas","doi":"10.1080/10550887.2025.2464356","DOIUrl":"https://doi.org/10.1080/10550887.2025.2464356","url":null,"abstract":"<p><p>This systematic review synthesizes current evidence on non-prescribed ketamine use, emphasizing its neurobiological impacts and psychotherapeutic interventions. Patterns of misuse demonstrate the complex interplay of neurobiological, socio-economic, demographic and psychological factors with adolescents, women and polysubstance users identified as high-risk groups. Neurobiological findings highlight prefrontal-limbic dysconnectivity, maladaptive neuroplasticity alongside hypothalamic-pituitary-adrenal (HPA) axis dysregulation as central mechanisms underlying this addiction. The review evaluates the comparative efficacy of psychotherapies whilst proposing an innovative framework that aligns therapeutic timing with neuroplastic recovery phases. Emerging evidence identifies biomarkers, e.g., brain-derived neurotrophic factor (BDNF) and heart rate variability (HRV), as promising tools for guiding personalized and phase-specific interventions. Gaps in research include the limited representation of low-resource settings and insufficient longitudinal data on biomarker integration and therapy sequencing. Recommendations propose a comprehensive neurobiologically informed model which carefully integrates digital platforms, culturally tailored strategies and biomarkers to enhance treatment outcomes.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"1-22"},"PeriodicalIF":1.6,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolomic insights into amphetamine-type stimulant misuse: unraveling biochemical pathways and biomarkers.","authors":"Ruzmayuddin Mamat, Baharudin Ibrahim, Rusdi Abd Rashid, Gareth Sim Maw Shin, Suzaily Wahab, Azmir Ahmad, Nuratikah M Nordin","doi":"10.1080/10550887.2025.2473188","DOIUrl":"https://doi.org/10.1080/10550887.2025.2473188","url":null,"abstract":"<p><p>Amphetamine-type stimulants (ATS), such as methamphetamine, amphetamine, and MDMA, are highly risky substances linked to neurochemical disruptions, metabolic disturbances, and systemic toxicity. Despite substantial research on their neurotoxic effects, the metabolic pathways involved in ATS dependence remain poorly understood. This study aimed to characterize the metabolic signatures associated with ATS dependence using NMR-based metabolomics to identify systemic metabolic disruptions related to chronic ATS use. A cross-sectional study was conducted involving 583 participants, comprising ATS-dependent individuals from Malaysian drug detention centers and healthy controls. Plasma samples were analyzed using 1H-NMR, CPMG, and HSQC spectroscopy to obtain comprehensive metabolomic profiles. Multivariate analyses, including PCA-X, OPLS-DA, and logistic regression, were employed to identify metabolites that differentiated ATS patients from controls. Metabolites were cross-referenced with BMRB and HMDB databases for validation. ATS-dependent individuals showed significant alterations in metabolic pathways, with reductions in cholic acid, L-valine, L-alanine, lactic acid, creatinine, histidine, taurine, and homovanillic acid (all <i>p</i> < .005), indicating disruptions in energy metabolism, neurotransmitter biosynthesis, and oxidative stress defenses. Elevated L-arginine levels (<i>p</i> < .001) suggested nitrogen metabolism dysregulation. OPLS-DA analysis demonstrated robust group separation (R²Y = 0.762, Q²Y = 0.756, AUROC = 0.987), with sensitivity, specificity, and classification accuracy of 86.9%, 97.4%, and 91.5%, respectively. This study presents the first NMR-based metabolomic profile of ATS misuse in Malaysia, identifying critical metabolic disruptions linked to chronic ATS use. Key biomarkers, including cholic acid, L-valine, and homovanillic acid, highlight potential targets for biomarker development and precision medicine strategies to improve the diagnosis, treatment, and understanding of ATS use disorder.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"1-12"},"PeriodicalIF":1.6,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatial analysis of methamphetamine and amphetamine use disorder among Alabama Medicaid recipients in rural and urban areas.","authors":"Haelim Jeong, Karen Johnson, Ellen Robertson, Andrew Aaflaq, Justin McDaniel, Shanna McIntosh, David L Albright","doi":"10.1080/10550887.2025.2464338","DOIUrl":"https://doi.org/10.1080/10550887.2025.2464338","url":null,"abstract":"<p><strong>Background: </strong>The current study uses geographic information system (GIS) methods to better understand structural risks significantly associated with substance misuse and how those risks may be driven by urbanicity versus rurality.</p><p><strong>Methods: </strong>Using Alabama Medicaid administrative claims data from January 1, 2015, to December 31, 2020, we identified Medicaid recipients with claims for methamphetamine use. Our dataset included 100% of claims for the 2015-2020 study period. County-level geocodes were also obtained for each Medicaid recipient aged > 18 years (<i>n</i> = 9,861). We added a rural-urban designation variable for each county by utilizing the rural-urban continuum codes from the United States Department of Agriculture.</p><p><strong>Results: </strong>Fifty-one counties (76.12%), specifically, had changes in methamphetamine use rates > 0% during the study period, with 10 (14.93%) counties exhibiting >100% increases in methamphetamine use rates. Findings suggest that Alabamians residing in rural portions of the state engaged in greater usage as compared with those in urban locations.</p><p><strong>Conclusion: </strong>Findings point to the need for intervention in rural Alabama targeting methamphetamine use. The development of prevention and intervention approaches that target risks stemming from geographical differences may bolster current efforts to reduce methamphetamine and other forms of substance misuse.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"1-9"},"PeriodicalIF":1.6,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe nasal spray oxymetazoline use disorder - a case report.","authors":"Alicia Collette Podwojniak, Kathy Chen, Benjamin Pullinger, Jaimy D Jabon, Andrea Garcia, Richard Jermyn","doi":"10.1080/10550887.2024.2430072","DOIUrl":"https://doi.org/10.1080/10550887.2024.2430072","url":null,"abstract":"<p><p>Oxymetazoline hydrochloride 0.05% is a lipophilic sympathomimetic nasal decongestant spray available over the counter (OTC) and commonly used for allergic and chronic rhinitis. A well-known side effect of these nasal sprays is rebound congestion termed rhinitis medicamentosa (RM), but there is little literature attesting to the relationship between RM and substance use disorder. This is a case report of severe nasal spray oxymetazoline use disorder per DSM-5 criteria discovered incidentally in a 44-year-old patient receiving care at a residential addiction treatment center for long-standing polysubstance use and bipolar disorders. The patient began using oxymetazoline in 2003 for allergic rhinitis and developed rhinitis medicamentosa that progressed to an oxymetazoline use disorder. Despite medical and clinical interventions, cravings and urges prevented her from stopping the nasal spray. We discuss the pharmacological properties of oxymetazoline, the behavioral aspects of its intranasal administration, and the drug-induced rebound congestion that may contribute to its misuse. To our knowledge, this is the first reported case of oxymetazoline use disorder lasting 20 years.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"1-5"},"PeriodicalIF":1.6,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Switching to levomethadone improves methadone-induced hyperhidrosis: A case report.","authors":"Tiziano Serfilippi, Silvia Piccirillo, Francesca Romagnoli, Marella Tarini, Vincenzo Lariccia, Simona Magi","doi":"10.1080/10550887.2024.2443696","DOIUrl":"https://doi.org/10.1080/10550887.2024.2443696","url":null,"abstract":"<p><p>Methadone maintenance therapy is the cornerstone of treatment for heroin addiction. Hyperhidrosis is a common and often-overlooked side effect of methadone. Different medications, such as antihistamines and anticholinergic drugs, have been reported to be effective against opioid-induced sweating, but there is no standardized therapy. A 51-year-old patient under methadone maintenance therapy reported long-standing hyperhidrosis, which worsened each time the methadone dosage was increased. After substituting methadone with levomethadone, while maintaining equivalent dosages, the patient reported a stark reduction in sweating. Therefore, levomethadone could be a promising alternative for patients in methadone maintenance therapy who suffer from methadone-induced hyperhidrosis.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"1-5"},"PeriodicalIF":1.6,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pilot study of ketamine among individuals with tobacco use disorder: tolerability and initial impact on tobacco use outcomes.","authors":"Janice Chuang, Riley Carpenter Lide, Nikhil Kamath, Alison Oliveto, Merideth Addicott","doi":"10.1080/10550887.2025.2450129","DOIUrl":"https://doi.org/10.1080/10550887.2025.2450129","url":null,"abstract":"<p><strong>Objectives: </strong>There is increasing evidence of ketamine's therapeutic potential in reducing substance use in individuals with substance use disorders. However, its effects on tobacco use disorder are unknown. We investigated the effect of a subanesthetic dose of ketamine on tobacco use.</p><p><strong>Methods: </strong>This randomized, single-blind, placebo-controlled, pilot study administered intravenous ketamine to individuals with tobacco use disorder recruited from the local community. Participants were randomized to receive either ketamine (0.5 mg/kg) (<i>n</i> = 6) or saline placebo (<i>n</i> = 4) over 20 min. Primary outcomes included measures of drug safety and tolerability during and within an hour after the infusion. Secondary outcomes included measures of tobacco use, craving, and withdrawal before, and 24-hours after, the drug infusion study day. A follow-up visit occurred eight days after the infusion.</p><p><strong>Results: </strong>Intravenous ketamine was well tolerated with transient side effects. No significant effects were noted on cigarette smoking, craving, or withdrawal symptoms on the post-infusion visit following overnight abstinence or on the follow-up visit (<i>p's</i> > 0.05).</p><p><strong>Conclusions: </strong>Although limited by the small sample size, this pilot study extends previous research on ketamine for substance use disorders. While ketamine was well tolerated in this sample, additional research testing different ketamine doses and administration routes is necessary to determine whether ketamine has therapeutic potential for tobacco use disorder.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"1-5"},"PeriodicalIF":1.6,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating remyelination compounds for new applications in opioid use disorder management.","authors":"Gouri Sharma, Quinn Wade, Nicholas M Graziane","doi":"10.1080/10550887.2025.2452691","DOIUrl":"https://doi.org/10.1080/10550887.2025.2452691","url":null,"abstract":"<p><p>Opioid use disorder (OUD) is associated with a reduction in brain white matter, affecting critical areas involved in decision-making, impulse control, and reward processing. The FDA has approved several drugs and natural compounds that enhance myelination, targeting oligodendrocyte progenitor cells (OPCs), directly enhancing oligodendrocyte (OL) function, or acting as cofactors for myelin production. This retrospective case study aimed to assess whether current clinical evidence supports the use of myelin-enhancing agents to promote remission in OUD. We evaluated a range of compounds with demonstrated effects on myelination, including muscarinic antagonists, cholesterol and lipid homeostatic agents, anti-aging drugs, immunomodulatory agents, anti-inflammatory medications, and others (25 medications in total), as well as 17 vitamins and supplements. Buprenorphine and methadone were used as positive controls. Sequential analyses were performed to identify individual drugs driving significant changes in remission rates (<i>p</i> ≤ 0.01; <i>N</i> ≥ 3,000) and their effects across age, sex, and Body Mass Index (BMI) categories. Three key findings emerged: (1) melatonin improved remission rates in males but showed no effect in females; (2) ibuprofen significantly increased remission rates, particularly in individuals aged 20-39 and 40-59 years; and (3) thiamin was associated with decreased remission rates in males and individuals with a BMI ranging from normal weight to obese. Additionally, buprenorphine and methadone were confirmed as effective in promoting remission. These findings highlight the importance of personalized medicine in treating OUD and suggest that further research is needed to explore individualized treatment strategies based on sex, age, and BMI.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"1-17"},"PeriodicalIF":1.6,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applying the theory of planned behavior to predict online addiction treatment intention.","authors":"Hagit Bonny-Noach, Dudi Gold, Ariel Caduri","doi":"10.1080/10550887.2023.2230834","DOIUrl":"10.1080/10550887.2023.2230834","url":null,"abstract":"<p><strong>Methods: </strong>This descriptive-analytical study included a self-report questionnaire based on the TPB model, and was distributed to a sample of 115 people recovering from SUD, aged 18-69, 62% of whom were men.</p><p><strong>Results: </strong>Attitude, Subjective Norms (SN), and Perceived Behavioral Control (PBC) toward online addiction treatment was significantly positive in relation to intention and past behavior of participants in online addiction treatment. Attitude and PBC were found to be significant predictors, and the TPB model was found to be significant {F (3,111) = 47.29, <i>p</i> < 0.01}, explaining 56% of the variance of intention for participants in online addiction treatment.</p><p><strong>Conclusion: </strong>As online treatment is a relatively new tool in addiction treatment, professionals and treatment providers should encourage beliefs, attitudes, moral norms, and perceived behavior control to increase intentions among future participants in online addiction treatment.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"24-31"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10431217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood pressure response to extended-release naltrexone in heroin and prescription opioid users and its implications for cardiovascular morbidity.","authors":"Zhenhao Shi, Daniel D Langleben, David Rott, Mark Albanese, Igor Elman","doi":"10.1080/10550887.2024.2327739","DOIUrl":"10.1080/10550887.2024.2327739","url":null,"abstract":"<p><strong>Background: </strong>Consuming opioid agonists is a risk factor for cardiovascular disease particularly in intravenous heroin users. The monthly injectable extended-release opioid antagonist, naltrexone (XR-NTX) is an effective treatment for opioid use disorder. The impact of opioid receptor blockade through XR-NTX on blood pressure, a critical risk factor for cardiovascular morbidity, has not yet been characterized.</p><p><strong>Methods: </strong>The study evaluated the change in blood pressure during XR-NTX treatment among 14 patients who predominately used intravenous heroin and 24 patients who used prescription oral opioids, all with opioid use disorder. Blood pressure was measured in each patient immediately before the first XR-NTX injection and ∼two weeks after the first injection. The change in diastolic and systolic pressure was compared between the heroin users and the prescription opioids users using analysis of variance.</p><p><strong>Results: </strong>XR-NTX treatment was associated with significant decreases in diastolic blood pressure in the heroin group, but not in the prescription opioids group. Systolic blood pressure values in the heroin users showed a decline at trend level only.</p><p><strong>Conclusions: </strong>Further research is warranted to replicate our findings and to determine whether XR-NTX effect is relatively specific to blood pressure or generalizes to other components of metabolic syndrome. Distinguishing between heroin and prescription opioid users could shed light on the unique clinical and pharmacological profiles of opioid drugs, particularly regarding their cardiovascular safety. This information can be useful in developing personalized therapeutic strategies based on the route of opioid administration.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"77-87"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140332178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}